Summary
The purpose of this study is to assess the safety and tolerability of XmAb®819 administered
intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell
renal cell carcinoma and to identify the minimum safe and biologically active dose and the
recommended dose (RD).